Genentech, Inc.

This study looks at whether people with multiple sclerosis can safely switch from their current anti-CD20 therapy to a new under-the-skin version of ocrelizumab. About 100 participants will be followed for up to 48 weeks to see if brain lesions stay stable and if they are satisfi…

This early-stage trial will test the safety and tolerability of a new drug, cevostamab, in 46 people with systemic lupus erythematosus, some of whom also have active lupus nephritis. The drug is given intravenously, and researchers will monitor side effects and how the drug moves…

This phase 3 trial is testing a daily pill called giredestrant in 300 people with early-stage, hormone-sensitive breast cancer who had side effects from standard aromatase inhibitors. The study will track how well patients stick with the treatment, any side effects, and changes i…

This study tests a new drug called GDC-1261 in 260 people with advanced or metastatic prostate cancer that has worsened after prior treatment. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors or lower PSA levels. Participants must alread…

This early-phase study tests a new drug called RO7851624 in 160 people with relapsed/refractory multiple myeloma who have tried several standard treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that the dr…

This early-stage study tests an experimental treatment called P-CD19CD20-ALLO1 in 162 adults with severe lupus that hasn't improved with standard therapies. The treatment uses specially engineered immune cells to target and potentially reset the immune system. The main goals are …